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Abstract
Background The LACE index—length of stay (L), acuity (A), Charlson co-morbidities (C), and emergent visits (E)—predicts
30-day outcomes following heart failure (HF) hospitalization but is complex to score. A simpler LE index (length of stay and
emergent visits) could offer a practical advantage in point-of-care risk prediction.
Methods and results This was a sub-study of the patient-centred care transitions in HF (PACT-HF) multicentre trial. The der-
ivation cohort comprised patients hospitalized for HF, enrolled in the trial, and followed prospectively. External validation was
performed retrospectively in a cohort of patients hospitalized for HF. We used log-binomial regression models with LACE or LE
as the predictor and either 30-day composite all-cause readmission or death or 30-day all-cause readmission as the outcomes,
adjusting only for post-discharge services. There were 1985 patients (mean [SD] age 78.1 [12.1] years) in the derivation cohort
and 378 (mean [SD] age 73.1 [13.2] years) in the validation cohort. Increments in the LACE and LE indices were associated with
17% (RR 1.17; 95% CI 1.12, 1.21; C-statistic 0.64) and 21% (RR 1.21; 95% CI 1.15, 1.26; C-statistic 0.63) increases, respectively,
in 30-day composite all-cause readmission or death; and 16% (RR 1.16; 95% CI 1.11, 1.20; C-statistic 0.64) and 18% (RR 1.18;
95% CI 1.13, 1.24; C-statistic 0.62) increases, respectively, in 30-day all-cause readmission. The LE index provided better risk
discrimination for the 30-day outcomes than did the LACE index in the external validation cohort.
Conclusions The LE index predicts 30-day outcomes following HF hospitalization with similar or better performance than the
more complex LACE index.
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Introduction
Heart failure (HF) is a common cause of hospitalization in
older adults. The period after hospitalization is one of high
risk, when patients commonly experience decompensation,
readmission, and death.1 Risk prediction can help identify pa-
tients who are at high risk of readmission or death and who
may benefit from close follow-up. Whereas several clinical
prognostic models have been developed to predict the risk
of readmission or death following hospitalization for HF, most
rely on retrospective administrative data and are difficult to
compute at the point of care.
The LACE index (length of stay, acuity, Charlson
co-morbidity index, and number of emergency department
[ED] visits within 6 months) was derived using administrative
data from patients who were discharged to the community
after a medical or surgical admission.2 In this population,
the LACE index, with a threshold score of 10, predicted the
risk of 30-day composite all-cause readmission or death with
reasonable discrimination (C-statistic 0.68). The LACE index
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has also been validated for use among patients hospitalized
for HF, with modest risk discrimination for 30-day composite
all-cause readmission or death (C-statistic 0.57)3 and an opti-
mal threshold of 13. The LACE index is currently used to iden-
tify at-risk patients in Ontario and other provinces to plan
services following hospital discharge.4
Although the LACE index is widely used, its application at
the point of care is limited by its complexity. The Charlson
(C) co-morbidity index includes 19 variables and requires a
chart review and computational aide. It is possible that
components such as acuity and Charlson co-morbidity do
not provide discriminative information among patients
hospitalized for HF. These patients typically present for hos-
pitalization via the ED, receiving a point for acuity, and are
multi-morbid, receiving several points for co-morbidities in-
cluding HF. A simplified score that omits acuity and
co-morbidities would represent a practical step forward in
risk prediction.
In this sub-study of the patient-centred care transitions in
HF (PACT-HF) trial,5 we assessed whether the LE index, a sum
of length of hospital stay (in days) and number of ED visits in
the preceding 6 months, can predict 30-day composite
all-cause readmission or death and 30-day all-cause readmis-
sion with comparable performance to the LACE index. We ex-
ternally validated the LE index and determined an optimal
threshold to stratify risk.
Methods
Study design
This was a prospective cohort sub-study of a multicentre
clinical trial.
Study population
The derivation cohort was a subset of patients hospitalized
for HF and enrolled in the multicentre PACT-HF stepped
wedge cluster randomized trial from February 2015 to March
2016.5,6 The study was approved by the research ethics
boards of all participating institutions with a waiver for writ-
ten consent. Eligible patients provided informed verbal con-
sent to participate in the study. This study complies with
the Declaration of Helsinki. This study follows the STROBE
guidelines for reporting observational data (Supplementary
file). The patients in the sub-study comprised a group who re-
ceived transitional care services in hospital and following
discharge.5 Transitional care services included nurse-led pa-
tient education and structured home visits. We included pa-
tients with a diagnosis of HF on admission, confirmed by
the nursing case manager with either the Boston criteria7 or
natriuretic peptide (BNP/NT-pro-BNP) levels who were
discharged between March 2015 and March 2016. We ex-
cluded patients who did not meet the diagnostic criteria for
HF, who died during hospitalization, or who were discharged
to another hospital.
The external validation was performed retrospectively in a
separate cohort of patients hospitalized for HF and enrolled
in the PACT-HF pilot study from March 2012 to July 2013.3
We excluded patients who did not meet the diagnostic
criteria for HF, who died during hospitalization, or who were
discharged to another hospital.
Data collection
We obtained clinical characteristics for analysis from hospital
charts and administrative databases held at ICES. ICES is an
independent, non-profit research institute whose legal status
under Ontario’s health information privacy law allows it to
collect and analyze health care and demographic data, with-
out consent, for health system evaluation and improvement.
We used a 5-year look-back period to identify baseline co-
morbidities. We identified inpatient services using the Cana-
dian Institute for Health Information Discharge Abstract Data-
base (CIHI-DAD) and deaths using the Ontario Registered
Persons Database (ORPD). These datasets were linked using
unique encoded identifiers and analysed at ICES.
Outcomes
Outcomes included 30-day composite all-cause readmission
or death and 30-day all-cause readmission.
Statistical analysis
We reported continuous variables using means (SD) and me-
dians (IQR) and categorical variables using numbers and
percentages.
We used log-binomial regression models with either the
LACE or LE index as the predictor, adjusted for receipt of
post-discharge home care or HF clinic services. We reported
relative risk (RR) and 95% confidence intervals (CI). We com-
pared the ability of the LACE and LE indices to discriminate
between patients at risk of 30-day outcomes using the C-
statistic.8 We assessed the model goodness of fit using the
Brier score.8–10 The Brier score is a measure of the accuracy
of predictive models for binary outcomes, with a score of 0
indicating perfect accuracy and a score of 1 indicating the
model is completely inaccurate.8
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Additional analyses
We fitted the same model for both 30-day composite
all-cause readmission or death and 30-day all-cause readmis-
sion using dichotomized LE index values above and below
various cut-points. We computed the RR (95% CI), C-statistic
(95% CI), sensitivity, specificity, positive likelihood ratio
(PLR), and negative likelihood ratio (NLR) for each model.
We used the closest to (0,1) criterion—defined as the mini-
mum Euclidean distance to (0,1), the point at which sensitiv-
ity and specificity are maximized on the receiver operating
characteristic (ROC) curve for a given outcome10—to deter-
mine the optimal threshold for the LE index.11
We internally validated each model with 100
bootstrapping resamples and computed the optimistic C-sta-
tistic. We externally validated the LE index by applying the
model that was developed in the derivation cohort in a sep-
arate cohort of patients and assessed model performance in
predicting each of the 30-day outcomes with the C-statistic
and the Brier score.8
We conducted analyses using SAS Version 9.4 for UNIX
(SAS Institute Inc., Cary, NC) and set the nominal significant
level for testing at 5%.
Results
Baseline characteristics
There were 1985 patients in the derivation cohort, and their
baseline characteristics are presented in Table 1. The mean
(SD) age of patients was 78.1 (12.1) years, and 49.4% were
female. The majority of patients (99.0%) presented for
hospitalization with high acuity (via the ED). Among patients
in the derivation cohort, 50.8% had diabetes, 75.9% had
hypertension, and 29.2% had prior PCI or CABG. All patients
received in-hospital transitional care services, and 47.7% of
patients were referred for post-discharge home care or HF
clinic services.
Outcomes
Of the 1985 patients in the derivation cohort, 458 patients
(23.1%) were readmitted or died, and 416 (21%) were
readmitted within 30 days of discharge. The mean (SD) LACE
index was 14.6 (2.7) among those who were readmitted or
Table 1 Clinical characteristics of the derivation and external validation cohorts
Characteristics Derivation cohort (n = 1985) Validation cohort (n = 378)
Demographics
Age (year), mean (SD) 78.1 (12.1) 73.1 (13.2)
Sex, n (%)
Male 1004 (50.6) 214 (56.6)
Women 981 (49.4) 164 (43.4)
Resides in long-term care, n (%) 160 (8.1) 30 (7.9)
Co-morbidities
Left ventricular ejection fraction, n (%) 48.0 (14.5) 40.9 (14.5)
Hypertension, n (%) 1506 (75.9) 288 (76.2)
Atrial fibrillation, n (%) 1118 (56.3) 199 (52.6)
Diabetes, n (%) 1008 (50.8) 197 (52.1)
Chronic kidney disease, n (%) 498 (25.1) 122 (32.3)
Prior PCI or CABG, n (%) 580 (29.2) 96 (25.4)
Chronic pulmonary disease, n (%) 488 (24.6) 85 (22.5)
Peripheral vascular disease, n (%) 214 (10.8) 62 (16.4)
Cerebrovascular disease, n (%) 208 (10.5) 76 (20.1)
Dementia, n (%) 194 (9.8) 42 (11.1)
Liver disease, n (%) 65 (3.3) 9 (2.4)
Cancer (any), n (%) 205 (10.3) 53 (14.0)
Resource utilization
High acuity admission (via ED), n (%) 1966 (99.0) 378 (100.0)
Number of ED visits in preceding 6 months, mean (SD) 2.5 (2.0) 1.5 (2.1)
Length of stay, mean (SD) 9.9 (11.0) 8.2 (6.8)
Charlson co-morbidity index, mean (SD) 4.4 (2.5) 4.1 (1.9)
Estimated risk
LE index, mean (SD) 6.8 (2.0) 5.7 (1.9)
LACE index, mean (SD) 13.6 (2.7) 12.7 (2.4)
CABG, coronary artery bypass grafting; ED, emergency department; LACE, length of stay, acuity, Charlson co-morbidity index, and number
of emergency department visits in the prior 6 months; LE, length of stay and number of emergency department visits in the prior
6 months; PCI, percutaneous coronary intervention.
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died and 13.3 (2.7) among those who were neither
readmitted nor died within 30 days. The mean (SD) LE index
was 7.5 (2.1) for those who were readmitted or died and
6.6 (1.9) for those who were neither readmitted nor died
within 30 days. The scoring of the LE index is described in
Figure 1.
30-day composite all-cause readmission or death
Each increment in the LACE index was associated with a 17%
increase in 30-day composite all-cause readmission or death
(RR 1.17; 95% CI 1.12, 1.21 per unit; C-statistic 0.64; 95% CI
0.61, 0.67) (Table 2). Each increment in the LE index was as-
sociated with a 21% increased risk of 30-day composite
all-cause readmission or death (RR 1.21; 95% CI 1.15, 1.26
per unit; C-statistic 0.63; 95% CI 0.59, 0.66). The LACE (Brier
score 0.17) and LE (Brier score 0.17) indices were well cali-
brated for 30-day composite all-cause readmission or death.
30-day all-cause readmission
Each increment in the LACE index was associated with a 16%
increase in 30-day all-cause readmission (RR 1.16; 95% CI
1.11, 1.20 per unit; C-statistic 0.64; 95% CI 0.60, 0.68). Incre-
ments in the LE index were associated with an 18% increased
risk for 30-day all-cause readmission (RR 1.18; 95% CI 1.13,
1.24 per unit; C-statistic 0.62; 95% CI 0.60, 0.66). The LACE
(Brier score 0.16) and LE (Brier score 0.16) indices were well
calibrated for 30-day all-cause readmission.
Figure 1 Scoring and performance of the LE index to predict 30-day outcomes in patients hospitalized for HF. In a sub-study of the Patient-centred
Care Transitions in Heart Failure multicentre trial, the LE index, comprising length of stay (L) and number of ED visits in preceding 6 months (E), pre-
dicted 30-day outcomes in patients hospitalized for HF with similar performance as the more complex LACE index. The index was externally validated in
a separate cohort.
Table 2 Performance of the LACE and LE indices in predicting 30-day all-cause readmission and 30-day composite all-cause readmission
or death in the derivation (n = 1985) and external validation (n = 387) cohorts
Risk index N with events (% of total) Relative risk (95% CI)a C-statistic (95% CI)b Brier scorec Optimistic C-statistic (95% CI)d
30-day composite all-cause readmission or death
LACE 458 (23%) 1.17 (1.12, 1.21) 0.64 (0.61, 0.67) 0.17 0.64 (0.61, 0.67)
LE 458 (23%) 1.21 (1.15, 1.26) 0.63 (0.59, 0.66) 0.17 0.63 (0.59, 0.66)
LEe 105 (28%) 1.18 (1.11, 1.27) 0.64 (0.58, 0.70) 0.19 NA
30-day all-cause readmission
LACE 416 (21%) 1.16 (1.11, 1.20) 0.64 (0.60, 0.68) 0.16 0.64 (0.60, 0.68)
LE 416 (21%) 1.18 (1.13, 1.24) 0.62 (0.60, 0.66) 0.16 0.62 (0.59, 0.66)
LEe 97 (26%) 1.21 (1.13, 1.31) 0.66 (0.60, 0.72) 0.18 NA
CI, confidence interval; LACE, length of stay, acuity, Charlson co-morbidity index, and number of emergency department visits in the prior
6 months; LE, length of stay and number of emergency department visits in the prior 6 months.
aAdjusted for post-discharge services.
bThe C-statistic is a measure of discrimination from 0 to 1 with higher scores indicating stronger discrimination.
cThe Brier score is a measure of model accuracy from 0 to 1, with lower scores indicating higher accuracy.
dThe optimism adjusted C-statistic is the result of internal validation by bootstrapping with 100 samples.
eExternal validation cohort.
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Optimal threshold for the LE index
A LE index of ≥7 (vs. <7) was associated with an 86% in-
creased risk of 30-day composite all-cause readmission or
death (RR 1.86; 95% CI 1.55, 2.22; C-statistic 0.60; 95% CI
0.57, 0.62) and a 73% increased risk of 30-day all-cause read-
mission (RR 1.73; 95% CI 1.43, 2.10; C-statistic 0.60; 95% CI
0.57, 0.63). Using the closest to (0,1) criterion, we suggest a
LE index threshold of ≥7 based on the minimum distance to
(0,1) on the ROC curve (Figure 2). A score ≥7 had a sensitivity
of 0.67, a specificity of 0.52, a PLR of 1.40, and a NLR of 0.63
for 30-day composite all-cause readmission or death. A score
≥7 yielded a sensitivity of 0.66 and a specificity of 0.52, a PLR
of 1.37, and a NLR of 0.65 for 30-day all-cause readmission.
The performance of the LE index at various cut-points is
depicted in Table 3.
Internal validation
In the internal validation with 100 bootstrap samples, the
LACE index had moderate discrimination for 30-day compos-
ite all-cause readmission or death (optimistic C-statistic 0.64;
95% CI 0.61, 0.67) and 30-day all-cause readmission (optimis-
tic C-statistic 0.64; 95% CI 0.60, 0.68). The LE index had mod-
erate discrimination for both 30-day composite all-cause
readmission or death (C-statistic 0.63; 95% CI 0.59, 0.66)
and 30-day all-cause readmission (optimistic C-statistic 0.62;
95% CI 0.59, 0.66).
External validation
There were 378 patients in the external validation cohort,
and their baseline characteristics are presented in Table 1.
The mean (SD) age was 73.1 (13.2) years, and 43.4% of all pa-
tients were female. Of the 378 patients, 76.2% had hyperten-
sion, 52.1% had diabetes, and 25.4% had prior PCI/CABG. In
this cohort, 97 (26%) were readmitted, 17 (4.5%) died, and
105 (28%) were either readmitted or died within 30 days of
discharge.
Figure 2 Receiver operating characteristic curve analysis of LE index
thresholds in predicting 30-day composite all-cause readmission or death
in 1985 patients hospitalized for HF. A threshold LE index of ≥7 has opti-
mal sensitivity and specificity for predicting 30-day composite all-cause
readmission or death in patients hospitalized for HF.
Table 3 Performance of the LE index at various cut-points among 1985 patients hospitalized for heart failure




(95% CI)b Sensitivity Specificity LR+ LR
Minimum
distancec
30-day composite all-cause readmission or death (458 events)
≥6 388/1478 (26%) 1.88 (1.48, 2.39) 0.57 (0.55, 0.60) 0.85 0.29 1.19 0.53 0.73
vs. < 6 70/507 (14%)
≥7 306/1034 (30%) 1.86 (1.55, 2.22) 0.60 (0.57, 0.62) 0.67 0.52 1.40 0.63 0.58
vs. < 7 152/951 (16%)
≥8 235/737 (32%) 1.78 (1.51, 2.10) 0.59 (0.57, 0.62) 0.51 0.67 1.56 0.73 0.59
vs. < 8 223/1248 (18%)
≥9 146/390 (37%) 1.89 (1.60, 2.24) 0.59 (0.56, 0.62) 0.32 0.84 1.99 0.81 0.70
vs. < 9 312/1595 (20%)
30-day all-cause readmission (416 events)
≥6 351/1478 (24%) 1.73 (1.35, 2.23) 0.59 (0.56, 0.62) 0.84 0.28 1.17 0.55 0.74
vs. < 6 65/507 (13%)
≥7 276/1034 (27%) 1.73 (1.43, 2.09) 0.60 (0.57, 0.63) 0.66 0.52 1.37 0.65 0.59
vs. < 7 140/951 (15%)
≥8 211/737 (29%) 1.66 (1.39, 1.98) 0.60 (0.57, 0.63) 0.51 0.66 1.51 0.74 0.60
vs. < 8 205/1248 (16%)
≥9 133/390 (34%) 1.83 (1.53, 2.19) 0.60 (0.57, 0.63) 0.32 0.84 1.95 0.81 0.70
vs. < 9 283/1595 (18%)
CI, confidence interval; LE, length of stay and number of emergency department visits in the prior 6 months; LR+, positive likelihood ratio;
LR, negative likelihood ratio.
aAdjusted for post-discharge care services.
bThe C-statistic is a measure of discrimination from 0 to 1 with higher scores indicating stronger discrimination.
cMinimum distance refers to the minimum distance to the (0,1) point on the receiver operating characteristic curve.
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The LACE index had modest discrimination for 30-day com-
posite all-cause readmission or death (C-statistic 0.57; 95% CI
0.51, 0.64) and 30-day all-cause readmission (C-statistic 0.59;
95% CI 0.52, 0.65). The LE index had greater discrimination
than the LACE index for 30-day composite all-cause readmis-
sion or death (C-statistic 0.64; 95% CI 0.58, 0.70) and 30-day
all-cause readmission (C-statistic 0.66; 95% CI 0.60, 0.72).
Each increment in the LE index predicted an 18% increased
risk of 30-day composite all-cause readmission or death (RR
1.18; 95% CI 1.11, 1.27) (Table 2) and a 21% increased risk
of 30-day all-cause readmission (RR 1.21; 95% CI 1.13,
1.31). The LE index was well calibrated for 30-day all-cause
readmission or death (Brier score 0.19) and 30-day all-cause
readmission (Brier score 0.18).
Discussion
In this sub-study of the multicentre PACT-HF trial of patients
hospitalized for HF, we found that the LE index—a sum of the
length of hospital stay and number of ED visits in the preced-
ing 6 months—predicted 30-day composite all-cause read-
mission or death and 30-day all-cause readmission following
hospital discharge. Risk discrimination using the LE index
was as good as the LACE index, with good model fit in the
derivation cohort. Compared to the derivation cohort, the ex-
ternal validation cohort of patients hospitalized for HF 2 years
prior to the PACT-HF trial were younger and had a slightly
lower burden of co-morbidities. Risk discrimination of the
LE index, as measured by the C-statistic, was better than that
of the LACE index in the validation cohort for both 30-day
composite all-cause readmission or death and 30-day all-
cause readmission.
The simplicity of the LE index—without loss of model per-
formance—is a major advantage over other risk prediction
models following hospitalization for HF. The LACE index
requires computation of the Charlson co-morbidity index,
which is difficult to estimate at the bedside and is not a ro-
bust predictor of outcome in patients admitted for HF.13
Other risk prediction models in patients hospitalized for HF
include the Enhanced Feedback for Effective Cardiac Treat-
ment (EFFECT) risk score,12 which includes 11 variables, and
the Medicare-endorsed Readmission Risk Score (RRS),13
which includes 37 variables. The LE index can be used at
the point of care on the day of hospital discharge to identify
high-risk patients who may benefit from closer follow-up. The
ease of use of the LE index may increase the number of refer-
rals of eligible, vulnerable patients to additional HF services
post-discharge.
The discrimination of the LE index was modest but compa-
rable or better than previously established risk prediction
models tested in patients hospitalized for HF. The LE index
had similar performance as the LACE index in the derivation
cohort and better discrimination than the LACE index in the
validation cohort. The LE index performs comparably to other
risk scores such as the RRS (C-statistic 0.62 for 30-day
composite all-cause readmission or death; 0.61 for 30-day
all-cause readmission)13 as well as a readmission risk model
derived from the Get With The Guidelines (GWTG) dataset
(C-statistic 0.59 for 30-day composite all-cause readmission
or death).14 Among patients hospitalized for HF in the GWTG
HF registry, machine learning approaches demonstrated
modest C-statistics of 0.59 to 0.62 for 30-day all-cause
readmission.15 Thus, the LE index represents an important
advantage over existing readmission risk prediction models,
offering ease of use without loss of discrimination. The mod-
est risk discrimination offered by risk prediction models in HF
for early readmissions—with C-statistics typically <0.65 even
for the most complex models—remains a challenge.
We derived and validated the LE index in hospitalized
patients who have a higher baseline risk than ambulatory
patients. The performance of this index cannot be compared
to risk models derived in ambulatory patients, who have a
wider spectrum of risk and therefore generate greater risk
discrimination when included in models.16 To date, a majority
of HF risk models were derived and validated in the
ambulatory setting, most are derived from administrative
data, and most predict 30-day HF-specific rather than all-
cause readmission.17 Although all-cause readmission is more
challenging to predict, it is a more relevant endpoint as up
to two-thirds of readmissions following hospitalization for
HF are for causes other than HF.18,19
Risk prediction models that include readmission as an end-
point have lower risk discrimination than those with mortal-
ity alone,22 as readmission may be related to unmeasured
variables such as clinical judgement, availability of hospital
beds,20 socio-economic status, and quality of post-discharge
care.14 A more complex risk prediction model derived from
administrative data offered the best discrimination for
30-day mortality (C-statistic 0.75), modest discrimination for
30-day composite readmission or death (C-statistic 0.62),
and low discrimination for 30-day readmission (C-statistic
0.59).21
Although the optimal threshold for the LE index to estab-
lish risk of the 30-day outcomes was 7, risk discrimination
was modest (C-statistic 0.60). A threshold of ≥7 met by 52%
of patients in our derivation cohort identified 67% of patients
who were readmitted or died within 30 days. The perfor-
mance of the threshold of ≥7 is better than the established
threshold for the LACE index in patients admitted for HF,
≥13, which identified 62% of patients who were readmitted
or died within 30 days.3 A threshold of ≥7 could be used as
a more reliable and practical criterion for referral to addi-
tional HF services than the LACE index.4
Our study has several strengths. First, the LE risk index was
derived from a reasonably large, multicentre trial in which
variations in post-discharge care were accounted for in the
model. Second, due to the limited exclusion criteria, the
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study population—elderly and with multiple medical co-mor-
bidities—was representative of clinical practice. Third, the
diagnosis of HF was confirmed by research nurses using
validated criteria, avoiding limitations associated with admin-
istrative data where up to 20% of patients may be incorrectly
classified as having or not having HF.22 Fourth, our predictor
index can be computed at the point of care without extensive
chart review, improving its relevance for clinical use. Lastly,
the results were externally validated in a separate population
of adults hospitalized for HF.
Limitations
Though our model was adjusted for the post-discharge transi-
tional care services received and HF clinic follow-up, we did
not adjust for other clinical characteristics. This is because
our goal was to develop and validate a simple, practical risk
index without the need for data extraction and computa-
tional aids that can limit uptake at the point of care. We
did not externally validate the optimal threshold for the LE
index as the cut-point analysis was exploratory. The perfor-
mance of the LE index at each cut-point should be interpreted
with caution in light of this limitation.
Conclusions
The simplified LE index is preferable to the LACE index for
predicting 30-day composite all-cause readmission or death
and 30-day all-cause readmission in patients admitted for
HF. It is easy to compute on the day of discharge, does not
require knowledge of clinical variables, has as good or better
discrimination than the LACE index, and retains the perfor-
mance of more complex risk prediction models. Although
there is a continuum of risk, a score of ≥7 may be used as
an optimal threshold for predicting 30-day composite all-
cause readmission or death and 30-day all-cause readmission.
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